NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19
The NIH has launched a major clinical trial to assess the malaria drug hydroxychloroquine and antibiotic azithromycin as a treatment for COVID-19. The trial will recruit 2,000 participants at 30 sites. A Q&A with the trial’s team leader: Davey Smith, MD, of UC San Diego School of Medicine.